Colon Pharmaceuticals announced that the holding subsidiary Colunbotai announced a number of innovative drug research results at the 2026 European Society of Medical Oncology Conference. The final analysis of the predetermined OS in the OptiTrop-Lung04 study showed that the median OS in the lucansatuzumab group was 25.9 months, 17.4 months in the platinum-containing dual-agent chemotherapy group, which was extended by 8.5 months, and the risk of death was reduced by 31%.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.